Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

SANOFI : EMA Recommends Approval Of Sanofi Pediatric Vaccine Hexyon/Hexacima 6-in-1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 01:58pm CEST

PARIS--The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended market approval for Sanofi Pasteur's 6-in-1 pediatric vaccine, French drugs giant Sanofi (>> SANOFI) said Friday.

MAIN FACTS:

- Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.

- The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur.

- The vaccine "reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur.

-Hexyon/Hexacima would be indicated for primary and booster vaccination of infants from six weeks of age in accordance with official recommendations.

- The CHMP positive opinion is supported by results of multi-center clinical studies involving approximately 5,000 infants; phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that HexyonTM/HexacimaTM is safe and induces a robust immune response against all six targeted diseases.

-Write to Mimosa Spencer at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
AQ
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
AQ
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
AQ
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
AQ
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
DJ
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
AQ
04/17SANOFI : CFO Contamine to retire later this year
RE
04/17SANOFI : Advent eyes acquisition of Sanofi’s Zentiva for EUR 1.9bn
AQ
04/17LAWMAKERS : Use P1.2 billion Sanofi refund for dengue patients
AQ
04/17SANOFI : Bank trio expected to lead financing on Zentiva sale
RE
More news
News from SeekingAlpha
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
04/17WALL STREET BREAKFAST : Tax Day At The Supreme Court 
04/17Fixing Drug Costs 
Financials (€)
Sales 2018 35 059 M
EBIT 2018 8 624 M
Net income 2018 4 942 M
Debt 2018 14 584 M
Yield 2018 4,67%
P/E ratio 2018 16,19
P/E ratio 2019 14,33
EV / Sales 2018 2,77x
EV / Sales 2019 2,60x
Capitalization 82 663 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,3 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-8.41%102 299
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.30%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.15%193 887
MERCK AND COMPANY4.71%158 813